Sugar consumption is declining in the U.S. and parts of Europe as GLP-1 weight-loss drugs such as Ozempic and Wegovy become more widely used. Is it a coincidence, or is the increase in GLP-1 drugs making an impact on the sugar industry?
GLP-1 use linked to lower sugar intake
Since GLP-1 drugs entered the mainstream around 2022–2023, multiple data points suggest a measurable reduction in sugar consumption. According to a February 2026 analysis by Reuters, global sugar demand has softened as users of GLP-1 medications report eating fewer calories overall, with a particularly sharp decline in cravings for sweets and sugary drinks.
Industry analysts cited by Reuters estimate that per-capita sugar consumption in the U.S. has fallen by roughly 5-8% over the past two years, a drop that coincides with rapid growth in GLP-1 prescriptions. (More than 15 million Americans are now estimated to be using GLP-1 drugs for weight loss or diabetes management.)
Beverage sales show early impact
The effects are especially visible in the beverage sector. Data referenced by Reuters show slowing growth (and in some cases outright declines) in full-sugar soda sales, particularly among higher-income consumers, who are more likely to have access to GLP-1 medications. Several major beverage companies have acknowledged shifting consumer preferences toward smaller portions, low-sugar formulations, and functional drinks.
In Europe, sugar taxes combined with GLP-1 uptake have amplified the effect, pushing sugar prices lower and forcing suppliers to reassess demand forecasts.
Industry prepares for long-term shift
Food manufacturers are now planning for a future in which reduced appetite and sugar avoidance become structural trends rather than short-term fluctuations. (Some food brands are even targeting products specifically towards GLP-1 users.)
Analysts told Reuters that if GLP-1 adoption continues at its current pace, global sugar demand growth could remain muted for years. While nutrition experts caution that long-term dietary impacts are still being studied, the early data suggest GLP-1 drugs are already changing what — and how much — people eat.
Links on this page may be affiliate links, for which the site earns a small commission, but the price for you is the same
Leave a Comment